The Hedge Funds and the Sweetheart Deal

Several hedge funds, including Baupost Group, participated in the recent private placement of clinical-stage biopharma company Translate Bio.

(Illustration by II)

(Illustration by II)

A clinical-stage biopharmaceutical company that went public about 11 months ago recently tapped a slew of hedge funds to raise money in a private placement. And at the moment it looks like a sweetheart deal for these investors, whose identities were disclosed in a regulatory filing earlier this week.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.